Related Experiment Videos
[Flow cytometry for testing chemosensitivity of malignant bone tumors]
1Department of Orthopaedics, First University Hospital, West China University of Medical Sciences, Chengdu 610041.
Objective:
To study chemosensitivity and multidrug resistance of malignant bone tumors and to make an individual protocol of chemotherapy with sensitive antitumor agents.
Methods:
Apoptosis induced by MTX, ADM, MMC, VP-16, VCR and CTX, and chemosensitivity in 32 fresh specimens of malignant bone tumors were analyzed by flow cytometry (FCM) and quantitative immunofluorescence. The expression of P-glycoprotein (P170) in the specimen and the relation between P170, multidrug resistance, and chemosensitivity were detected.
Results:
The rate of apoptosis was significantly different in malignant bone tumor cells treated with different drugs: MTX (30.50 +/- 10.22)%, ADM (26.28 +/- 9.35)%, MMC (23.11 +/- 7.38)%, VP-16 (18.17 +/- 6.14)%, VCR (4.44 +/- 2.55)%, and CTX (1.22 +/- 0.59)%. The individual variation of cell apoptosis was prominent in the specimens of same pathological type treated with same agent. There was lower chemosensitivity in the malignant bone tumors with a high expression of P170.
Conclusions:
Chemosensitivity testing by flow cytometry is a simple, quick and sensitive assay. Quantitative analysis of expression of P170 could be used to predict multidrug resistance and its chemosensitivity of malignant bone tumors.
Insights
Chemosensitivity testing using flow cytometry effectively predicts multidrug resistance in malignant bone tumors. Quantitative analysis of P-glycoprotein (P170) expression aids in tailoring chemotherapy protocols for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Malignant bone tumors exhibit variable responses to chemotherapy.
- Multidrug resistance (MDR) is a significant challenge in treating these cancers.
- Personalized chemotherapy protocols are needed to improve treatment efficacy.
Purpose of the Study:
- To assess the chemosensitivity and multidrug resistance of malignant bone tumors.
- To develop individualized chemotherapy protocols using sensitive antitumor agents.
- To investigate the role of P-glycoprotein (P170) in drug resistance.
Main Methods:
- Chemosensitivity and apoptosis were analyzed in 32 fresh malignant bone tumor specimens using flow cytometry (FCM) and quantitative immunofluorescence.
- The expression of P-glycoprotein (P170) was detected.
- Apoptosis was induced by Methotrexate (MTX), Adriamycin (ADM), Mitomycin C (MMC), Etoposide (VP-16), Vincristine (VCR), and Cyclophosphamide (CTX).
Main Results:
- Significant differences in apoptosis rates were observed across different chemotherapeutic agents.
- Methotrexate (MTX) induced the highest apoptosis rate (30.50 +/- 10.22%), while Cyclophosphamide (CTX) showed the lowest (1.22 +/- 0.59%).
- High expression of P-glycoprotein (P170) correlated with lower chemosensitivity in malignant bone tumors.
Conclusions:
- Flow cytometry is a simple, rapid, and sensitive method for chemosensitivity testing in malignant bone tumors.
- Quantitative analysis of P170 expression can predict multidrug resistance and guide chemotherapy selection.
- Individualized treatment strategies based on chemosensitivity testing can optimize chemotherapy for bone cancer patients.